$マインド メディシン マインドメッド(MNMD.US)$Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S. Benzinga· just GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life- -People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD- -Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
$マインド メディシン マインドメッド(MNMD.US)$ NEWS MindMed Reports First Quarter 2024 Financial Results and Business Updates MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks. The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026. MindMed is on track to begin its ...
The FDA breakthrough status and positive trial results for MM120 are seen as significant developments for Mind Medicine, leading to a surge in its stock price and an increased price target from Roth Capital Partners.
Jaguar8 : I concur on findings!